作者
Francesco Caiazza, Patricia M McGowan, Maeve Mullooly, Alyson Murray, Naoise Synnott, Norma O'Donovan, Louise Flanagan, Christopher J Tape, Gillian Murphy, John Crown, Michael J Duffy
发表日期
2015/6
期刊
British Journal of Cancer
卷号
112
期号
12
页码范围
1895-1903
出版商
Nature Publishing Group
简介
Background:
Identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), that is, breast cancers negative for oestrogen receptors, progesterone receptors and HER2 amplification, is currently one of the most urgent problems in breast cancer treatment. EGFR is one of the best-validated driver genes for TNBC. EGFR is normally activated following the release of ligands such as TGFα, mediated by the two MMP-like proteases ADAM (a disintegrin and metalloproteinase)-10 and ADAM-17. The aim of this study was to investigate the antitumour effects of a monoclonal antibody against ADAM-17 on an in vitro model of TNBC.
Methods:
We investigated an inhibitory cross-domain humanised monoclonal antibody targeting both the catalytic domain and the cysteine-rich domain of ADAM17-D1 (A12) in the HCC1937 and HCC1143 cell lines.
Results:
D1 (A12) was found to significantly inhibit the …
学术搜索中的文章
F Caiazza, PM McGowan, M Mullooly, A Murray… - British Journal of Cancer, 2015